Abstract
Aims
Clinical outcome may differ owing to the distinct pharmacological characteristics of insulin sensitizers and insulin. This study was performed to compare the metabolic and renal function changes with add-on pioglitazone treatment versus basal insulin in patients with type 2 diabetes mellitus (DM) in whom sulfonylurea and metformin regimens failed.
Methods
Patients who were consecutively managed in the diabetes comprehensive program with add-on pioglitazone or detemir/glargine treatment for at least 2 years following sulfonylurea and metformin treatment failure were included.
Results
A total of 1002 patients were enrolled (pioglitazone: 559, detemir: 264, glargine: 179). After propensity score matching, there were 105 patients with matchable baseline characteristics in each group. After a mean of 3.5 years of follow-up, the pioglitazone group showed a greater HbA1c reduction than the detemir group and the glargine group. Despite patients in all three groups exhibiting significant body weight gain, those in the pioglitazone group and the glargine group showed greater body weight increases than the patients in the detemir group (2.1, 1.6 and 0.8 kg, respectively, p < 0.05). Interestingly, Cox regression analysis indicated that patients under detemir or glargine treatment had a higher probability of CKD progression as compared with the pioglitazone group, with hazard ratios of 2.63 (95% CI 1.79–3.88) and 3.13 (95% CI 2.01–4.87), respectively.
Conclusions
Our study first showed that treatment with both pioglitazone and basal insulin improved glycemic control, while only pioglitazone treatment was observed to be advantageous in terms of preserving renal function when used as an add-on therapy for patients with type 2 DM in whom sulfonylurea and metformin regimens failed.
Similar content being viewed by others
References
Defronzo RA (2009) Banting lecture. From the triumvirate to the ominous octet: a new paradigm for the treatment of type 2 diabetes mellitus. Diabetes 58(4):773–795
Genuth S (2015) Should sulfonylureas remain an acceptable first-line add-on to metformin therapy in patients with type 2 diabetes? No, it’s time to move on! Diabetes Care 38(1):170–175
Inzucchi SE, Bergenstal RM, Buse JB et al (2012) Management of hyperglycaemia in type 2 diabetes: a patient-centered approach. Position statement of the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). Diabetologia 55(6):1577–1596
Abrahamson MJ (2015) Should sulfonylureas remain an acceptable first-line add-on to metformin therapy in patients with type 2 diabetes? Yes, they continue to serve us well! Diabetes Care 38(1):166–169
Inzucchi SE, Bergenstal RM, Buse JB et al (2015) Management of hyperglycemia in type 2 diabetes, 2015: a patient-centered approach: update to a position statement of the American Diabetes Association and the European Association for the Study of Diabetes. Diabetes Care 38(1):140–149
McIntosh B, Cameron C, Singh SR, Yu C, Dolovich L, Houlden R (2012) Choice of therapy in patients with type 2 diabetes inadequately controlled with metformin and a sulphonylurea: a systematic review and mixed-treatment comparison meta-analysis. Open Med 6(2):e62–74
Gross JL, Kramer CK, Leitao CB et al (2011) Effect of antihyperglycemic agents added to metformin and a sulfonylurea on glycemic control and weight gain in type 2 diabetes: a network meta-analysis. Ann Intern Med 154(10):672–679
August P, Hardison RM, Hage FG et al (2014) Change in albuminuria and eGFR following insulin sensitization therapy versus insulin provision therapy in the BARI 2D study. Clin J Am Soc Nephrol 9(1):64–71
Swinnen SG, Simon AC, Holleman F, Hoekstra JB, Devries JH (2011) Insulin detemir versus insulin glargine for type 2 diabetes mellitus. Cochrane Database Syst Rev (7):CD006383. doi:10.1002/14651858.CD006383.pub2
Chang YH, Lei CC, Lin KC, Chang DM, Hsieh CH, Lee YJ (2016) Serum uric acid level as an indicator for CKD regression and progression in patients with type 2 diabetes mellitus-a 4.6-year cohort study. Diabetes Metab Res Rev 32(6):557–564
Levey AS, Stevens LA, Schmid CH et al (2009) A new equation to estimate glomerular filtration rate. Ann Intern Med 150(9):604–612
National Kidney F (2002) K/DOQI clinical practice guidelines for chronic kidney disease: evaluation, classification, and stratification. Am J Kidney Dis 39(2 Suppl 1):S1–266
Kirsztajn GM, Suassuna JH, Bastos MG (2009) Dividing stage 3 of chronic kidney disease (CKD): 3A and 3B. Kidney Int 76(4):462–463; author reply 463–464
American Diabetes A (2013) Standards of medical care in diabetes-2013. Diabetes Care 36(Suppl 1):S11–66
Rassen JA, Shelat AA, Franklin JM, Glynn RJ, Solomon DH, Schneeweiss S (2013) Matching by propensity score in cohort studies with three treatment groups. Epidemiology 24(3):401–409
Koppe L, Pelletier CC, Alix PM et al (2014) Insulin resistance in chronic kidney disease: new lessons from experimental models. Nephrol Dial Transpl 29(9):1666–1674
Chen J, Muntner P, Hamm LL et al (2003) Insulin resistance and risk of chronic kidney disease in nondiabetic US adults. J Am Soc Nephrol 14(2):469–477
Jing C, Xu S, Ming J et al (2015) Insulin resistance is not independently associated with chronic kidney disease in Chinese population: a population-based cross-sectional study. Clin Chim Acta 448:232–237
Peng XH, Liang PY, Ou SJ, Zu XB (2014) Protective effect of pioglitazone on kidney injury in diabetic rats. Asian Pac J Trop Med 7(10):819–822
Ochodnicky P, Mesarosova L, Cernecka H et al (2014) Pioglitazone, a PPARgamma agonist, provides comparable protection to angiotensin converting enzyme inhibitor ramipril against adriamycin nephropathy in rat. Eur J Pharmacol 730:51–60
Fernandez-Real JM, Vendrell J, Garcia I, Ricart W, Valles M (2012) Structural damage in diabetic nephropathy is associated with TNF-alpha system activity. Acta Diabetol 49(4):301–305
Monroy A, Kamath S, Chavez AO et al (2009) Impaired regulation of the TNF-alpha converting enzyme/tissue inhibitor of metalloproteinase 3 proteolytic system in skeletal muscle of obese type 2 diabetic patients: a new mechanism of insulin resistance in humans. Diabetologia 52(10):2169–2181
Tripathy D, Daniele G, Fiorentino TV et al (2013) Pioglitazone improves glucose metabolism and modulates skeletal muscle TIMP-3-TACE dyad in type 2 diabetes mellitus: a randomised, double-blind, placebo-controlled, mechanistic study. Diabetologia 56(10):2153–2163
Jin HM, Pan Y (2007) Renoprotection provided by losartan in combination with pioglitazone is superior to renoprotection provided by losartan alone in patients with type 2 diabetic nephropathy. Kidney Blood Press Res 30(4):203–211
Petrica L, Vlad A, Petrica M et al (2011) Pioglitazone delays proximal tubule dysfunction and improves cerebral vessel endothelial dysfunction in normoalbuminuric people with type 2 diabetes mellitus. Diabetes Res Clin Pract 94(1):22–32
Dormandy JA, Charbonnel B, Eckland DJ et al (2005) Secondary prevention of macrovascular events in patients with type 2 diabetes in the PROactive Study (PROspective pioglitAzone Clinical Trial In macroVascular Events): a randomised controlled trial. Lancet 366(9493):1279–1289
Schneider CA, Ferrannini E, Defronzo R, Schernthaner G, Yates J, Erdmann E (2008) Effect of pioglitazone on cardiovascular outcome in diabetes and chronic kidney disease. J Am Soc Nephrol 19(1):182–187
Pugliese G (2014) Updating the natural history of diabetic nephropathy. Acta Diabetol 51(6):905–915
Chan DT, Watts GF, Irish AB, Dogra GK (2011) Rosiglitazone does not improve vascular function in subjects with chronic kidney disease. Nephrol Dial Transplant 26(11):3543–3549
Davies MJ, Gagliardino JJ, Gray LJ, Khunti K, Mohan V, Hughes R (2013) Real-world factors affecting adherence to insulin therapy in patients with Type 1 or Type 2 diabetes mellitus: a systematic review. Diabet Med 30(5):512–524
Miyazaki Y, Mahankali A, Matsuda M et al (2002) Effect of pioglitazone on abdominal fat distribution and insulin sensitivity in type 2 diabetic patients. J Clin Endocrinol Metab 87(6):2784–2791
Russo GT, De Cosmo S, Viazzi F et al (2016) Plasma triglycerides and HDL-C levels predict the development of diabetic kidney disease in subjects with type 2 diabetes: the AMD annals initiative. Diabetes Care 39(12):2278–2287
Brod M, Rana A, Barnett AH (2012) Adherence patterns in patients with type 2 diabetes on basal insulin analogues: missed, mistimed and reduced doses. Curr Med Res Opin 28(12):1933–1946
Farsaei S, Radfar M, Heydari Z, Abbasi F, Qorbani M (2014) Insulin adherence in patients with diabetes: risk factors for injection omission. Prim Care Diabetes 8(4):338–345
Acknowledgements
The authors thank Felix Thoemmes, Department of Human Development, Cornell University, Ithaca, NY, for the development of the propensity score matching program for SPSS.
Funding
This research did not receive any specific grant from any funding agency in the public, commercial or not-for-profit sector.
Author contributions
YHC and DWH contributed to the acquisition, analysis, interpretation of the data and the development of the manuscript. DMC contributed to the acquisition and analysis of the data. ALW and CHH contributed to the discussion. YJL contributed to the discussion and reviewed/edited the manuscript.
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Conflicts of interest
Y.-H. Chang, D.-M. Chang and Y.-J. Lee received speaking fees from NovoNordisk and Sanofi.
Human and animal rights disclosure
All procedures performed in studies involving human participants were in accordance with the ethical standards of the Institutional Review Board of Tri-Service General Hospital and with the 1964 Helsinki Declaration and its later amendments or comparable ethical standards.
Informed consent
Formal consent is not required for this retrospective study.
Data availability statements
The datasets during and/or analyzed during the current study available from the corresponding author on reasonable request.
Additional information
Managed by Massimo Porta.
Yu-Hung Chang and Der-Wei Hwu contributed equally.
Electronic supplementary material
Below is the link to the electronic supplementary material.
Rights and permissions
About this article
Cite this article
Chang, YH., Hwu, DW., Chang, DM. et al. Renal function preservation with pioglitazone or with basal insulin as an add-on therapy for patients with type 2 diabetes mellitus. Acta Diabetol 54, 561–568 (2017). https://doi.org/10.1007/s00592-017-0983-0
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00592-017-0983-0